Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry

被引:73
作者
Gabay, Cem [1 ,2 ]
Riek, Myriam [3 ]
Scherer, Almut [3 ]
Finckh, Axel [1 ]
机构
[1] Univ Hosp Geneva, Dept Med Specialties, Div Rheumatol, CH-1211 Geneva 14, Switzerland
[2] Univ Geneva, Sch Med, Dept Pathol & Immunol, CH-1211 Geneva, Switzerland
[3] Swiss Clin Qual Management Fdn, Zurich, Switzerland
关键词
rheumatoid arthritis; biologic DMARD; monotherapy; combination therapy; TOCILIZUMAB MONOTHERAPY; MULTIPLE IMPUTATION; INADEQUATE RESPONSE; DISEASE-ACTIVITY; METHOTREXATE; EFFICACY; THERAPY; IMMUNOGENICITY; INHIBITORS; RITUXIMAB;
D O I
10.1093/rheumatology/kev019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To determine the frequency of use of biologic DMARDs (bDMARDs) in monotherapy, to describe the baseline characteristics of patients treated with bDMARDs in monotherapy and to compare the effectiveness of bDMARDs in monotherapy with that of bDMARDs in combination with synthetic DMARDs (sDMARDs). Methods. Using data from the Swiss RA (SCQM-RA) registry, bDMARD treatment courses (TCs) were classified either as monotherapy or as combination therapy, depending on the presence of concomitant sDMARDs. Prescription of bDMARD monotherapy was analysed using logistic regression. bDMARD retention was analysed using Kaplan-Meier and Cox models with the addition of time-varying covariate effects. Evolution of the DAS28 over time was analysed with mixed-effects models for longitudinal data. Results. A total of 4218 TCs on bDMARDs from 3111 patients were included, of which 1136 TCs (27%) were initiated as monotherapy. bDMARD monotherapy was preferentially prescribed to older, co-morbid patients with longer disease duration, lower BMI, more active disease and more previous bDMARDs. After adjusting for potential confounding factors, drug retention was significantly lower in monotherapy [hazard ratio 1.15 (95% CI: 1.03, 1.30)]. Other factors such as type of bDMARD and calendar year of prescription were associated with a stronger effect on drug retention. Response to treatment in terms of DAS28 evolution was also slightly but significantly less favourable in monotherapy (P = 0.04). Conclusion. Our data suggest that bDMARD monotherapy is prescribed to more complex cases and is significantly less effective than bDMARD therapy in combination with sDMARDs, but to an extent that is clinically only marginally relevant.
引用
收藏
页码:1664 / 1672
页数:9
相关论文
共 29 条
[1]   Multiple imputation for missing data - A cautionary tale [J].
Allison, PD .
SOCIOLOGICAL METHODS & RESEARCH, 2000, 28 (03) :301-309
[2]   Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists [J].
Askling, Johan ;
Fored, C. Michael ;
Brandt, Lena ;
Baecklund, Eva ;
Bertilsson, Lennart ;
Feltelius, Nils ;
Coster, Lars ;
Geborek, Pierre ;
Jacobsson, Lennart T. ;
Lindblad, Staffan ;
Lysholm, Jorgen ;
Rantapaa-Dahlqvist, Solbritt ;
Saxne, Tore ;
van Vollenhoven, Ronald F. ;
Klareskog, Lars .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (10) :1339-1344
[3]   Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice [J].
Cannon, Grant W. ;
Mikuls, Ted R. ;
Hayden, Candace L. ;
Ying, Jian ;
Curtis, Jeffrey R. ;
Reimold, Andreas M. ;
Caplan, Liron ;
Kerr, Gail S. ;
Richards, J. Steuart ;
Johnson, Dannette S. ;
Sauer, Brian C. .
ARTHRITIS CARE & RESEARCH, 2011, 63 (12) :1680-1690
[4]   Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration [J].
Chatzidionysiou, Katerina ;
Lie, Elisabeth ;
Nasonov, Evgeny ;
Lukina, Galina ;
Hetland, Merete Lund ;
Tarp, Ulrik ;
van Riel, Piet L. C. M. ;
Nordstrom, Dan C. ;
Gomez-Reino, Juan ;
Pavelka, Karel ;
Tomsic, Matija ;
Kvien, Tore K. ;
van Vollenhoven, Ronald F. ;
Gabay, Cem .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (03) :374-377
[5]   Joint Damage Progression in Patients with Rheumatoid Arthritis in Clinical Remission. Do Biologics Perform Better Than Synthetic Antirheumatic Drugs? [J].
Ciubotariu, Elena ;
Gabay, Cem ;
Finckh, Axel .
JOURNAL OF RHEUMATOLOGY, 2014, 41 (08) :1576-1582
[6]   Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) [J].
Dougados, Maxime ;
Kissel, Karsten ;
Sheeran, Tom ;
Tak, Paul P. ;
Conaghan, Philip G. ;
Martin Mola, Emilio ;
Schett, Georg ;
Amital, Howard ;
Navarro-Sarabia, Federico ;
Hou, Antony ;
Bernasconi, Corrado ;
Huizinga, T. W. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (01) :43-50
[7]   Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].
Edwards, JCW ;
Szczepanski, L ;
Szechinski, J ;
Filipowicz-Sosnowska, A ;
Emery, P ;
Close, DR ;
Stevens, RM ;
Shaw, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581
[8]   Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis [J].
Emery, Paul ;
Sebba, Anthony ;
Huizinga, Tom W. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (12) :1897-1904
[9]   Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial [J].
Gabay, Cem ;
Emery, Paul ;
van Vollenhoven, Ronald ;
Dikranian, Ara ;
Alten, Rieke ;
Pavelka, Karel ;
Klearman, Micki ;
Musselman, David ;
Agarwal, Sunil ;
Green, Jennifer ;
Kavanaugh, Arthur .
LANCET, 2013, 381 (9877) :1541-1550
[10]   The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis [J].
Garces, Sandra ;
Demengeot, Jocelyne ;
Benito-Garcia, Elizabeth .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (12) :1947-1955